• STUDIES
    Participation is open to worldwide institutions.
    Read More
  • MEETINGS
    Since 1998, an Annual Meeting of the IELSG investigators has been regularly held.
    Read More
  • NEWSLETTER
    The IELSG Newsletter informs about studies, meetings and other research activities.
    Read More
  • PUBLICATIONS
    The results are presented to major congresses and published into peer-reviewed journals.
    Read More

Fighting cancer through research. You can support us by making a donation, however large or small.

Support Us

LATEST NEWS

  • IELSG48
    IELSG48Phase 3, interventional, multicentre, open-label, randomized study comparing rituximab plus zanubrutinib to rituximab monotherapy in previously untreated, symptomatic splenic marginal zone lymphoma (RITZ)
    Participants required:120
    Investigator responsible(s):D. Rossi
    Objective(s):The objectives of this trial are: to evaluate the efficacy of the addition of zanubrutinib to rituximab versus rituximab monotherapy in subjects with previously untreated SMZL in terms of Progression-Free Survival (PFS), to evaluate the activity of the addition of zanubrutinib to rituximab vs rituximab monotherapy in subjects with previously untreated SMZL in terms of Overall Response Rate (ORR), Duration of Response (DoR), and Overall Survival (OS), and to evaluate the safety profile of the addition of zanubrutinib to rituximab versus rituximab monotherapy in subjects with previously untreated SMZL.
    Lay summary:Splenic marginal zone lymphoma (SMZL) is a slow-growing tumor affecting B lymphocytes, a type of white blood cell.
    Recommended treatments usually include rituximab alone or spleen removal. Rituximab plus chemotherapy, although effective, has more side effects.
    The clinical trial evaluates whether zanubrutinib (a drug that blocks uncontrolled proliferation of the tumor cells) plus rituximab is more effective and safer than rituximab alone for treating SMZL.
    This randomized trial is enrolling 120 participants to receive either the combination or rituximab alone.
    Eligibility requires untreated SMZL, good general health, and adherence to contraceptive guidelines.
  • IELSG Annual Meeting 2025

    The Annual Meeting of the International Extranodal Lymphoma Study Group (IELSG) will be held on March 7-8, 2025 in Stresa (Italy) at Hotel La Palma.

    REGISTRATION is open.


ONGOING STUDIES

  • IELSG48
    IELSG48 Phase 3, interventional, multicentre, open-label, randomized study comparing rituximab plus zanubrutinib to rituximab monotherapy in previously untreated, symptomatic splenic marginal zone… Read more: IELSG48
  • IELSG50
    IELSG50 Pembrolizumab and radiotherapy for previously untreated patients with limited-stage NK/T cell lymphoma who are not eligible for chemotherapy Participants required: 30… Read more: IELSG50
  • IELSG45
    IELSG45 Randomized phase II trial on fitness- and comorbidity-tailored treatment in elderly patients with newly diagnosed primary CNS lymphoma (FIORELLA Trial) Participants… Read more: IELSG45

LATEST NEWSLETTER

PUBLICATIONS

Top